Page 5 - Head External News Today

Investegate announcements from Santhera Pharmaceuticals Holdi, Santhera to Announce 2020 Results on April 29, 2021

Pratteln, Switzerland, March 10, 2021 - Santhera Pharmaceuticals (SIX: SANN) announces that it has issued 480,708 treasury shares. The number of shares recorded in the commercial register has been increased

Santhera Pharmaceuticals Holding AG: Santhera Announces Results of Bondholders Meeting Pratteln, Switzerland, March 9, 2021 - Santhera Pharmaceuticals (SIX: SANN) announces that while a large majority of 89 % of bondholders represented at yesterdays bondholders meeting voted in favor of the resolutions proposed by the Company, the required threshold of 2/3 of all bonds outstanding to pass such resolutions was not met. Bondholders may still cast their vote for the resolution that would enable a...

German NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO. Pratteln, Switzerland, March 9, 2021 – Santhera Pharmaceuticals (SIX: SANN) announces that while a large majority of 89 % of bondholders represented at yesterday’s bondholders’ meeting voted in favor of the resolutions proposed by the Company, the required threshold of 2/3 of all bonds outstanding to pass such resolutions was not met. Bondholders ma...

(2) Pratteln, Switzerland, March 3, 2021 - Santhera Pharmaceuticals (SIX: SANN) announces that the last patient has completed the last visit for the first period of the placebo-controlled pivotal VISION-DMD study with vamorolone in patients with Duchenne muscular dystrophy (DMD), conducted by partner ReveraGen Biopharma Inc. Subject to a positive 6-month topline data readout of this first study phase, this could allow for a regulatory submission to the US FDA in Q1-2022 with the potential to of...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO. Pratteln, Switzerland, February 24, 2021 - Santhera Pharmaceuticals

German NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO. Pivotal 6-month data readout for vamorolone in Duchenne muscular dystrophy (DMD) expected in the second quarter of 2021 Organization streamlined with a focus on cost savings and progressing vamorolone Preliminary unaudited result for 2020: net sales CHF 15.0 million; net loss CHF 71.2 million; cash on hand as of December 31, 2020, CHF 12.4 million Upsiz...

Santhera Pharmaceuticals Holding AG: Santhera Announces Corporate Update and Proposal to Strengthen Capital Structure NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO. Pivotal 6-month data readout for vamorolone in Duchenne muscular dystrophy (DMD) expected in the second quarter of 2021 Organization streamlined with a focus on cost savings and progressing vamorolone Preliminary unaudited result for 2020: net sale...